Radiopharm Theranostics Announces Data From Brain Metastases Detection With RAD 101 Using PET-mpMRI In 22 Patients, All Detected With High Tumor-To-Background Ratio; Phase 2b Trial Now Recruiting In U.S.

• Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.
• All brain metastases, regardless of whether they were previously treated with radiation and the tumor of origin, were detected with RAD101, demonstrating a high tumor-to-background ratio.
• A Phase 2b imaging study to evaluate the diagnostic performance of RAD 101 in individuals with suspected recurrent brain metastases is currently recruiting in the United States.
  
   

SYDNEY, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics ((ASX:RAD, NASDAQ:RADX), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the publication of a novel imaging approach demonstrating proof-of-concept for the use of RAD 101 for successful detection of brain metastases (both treatment-naïve and previously treated) from a variety of primary solid tumors.